In OS and DFS evaluation, the 2-year survival was analyzed according to DAPK and MGMT methylation status, clinical staging and tumor size (T) and lymph node metastasis (N). This evidence concerns the gene DAPK1 and metastatic malignant neoplasm in the lymph nodes.